| Not Yet Recruiting | Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma NCT07110233 | University of California, San Francisco | N/A |
| Recruiting | Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combinatio NCT07227012 | Pfizer | Phase 1 / Phase 2 |
| Withdrawn | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With NCT06690281 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receivin NCT06899152 | Montefiore Medical Center | N/A |
| Not Yet Recruiting | A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellul NCT06935175 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adul NCT06858813 | AbbVie | Phase 1 |
| Recruiting | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369 | 7 Hills Pharma, LLC | Phase 1 / Phase 2 |
| Recruiting | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors NCT06239194 | ModeX Therapeutics, An OPKO Health Company | Phase 1 / Phase 2 |
| Recruiting | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatop NCT05451043 | AHS Cancer Control Alberta | Phase 2 |
| Recruiting | SIRT With Tremelimumab and Durvalumab for Resectable HCC NCT05701488 | Jiping Wang, MD, PhD | Phase 1 |
| Recruiting | Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan NCT05185505 | The Methodist Hospital Research Institute | Phase 4 |
| Active Not Recruiting | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With NCT05438420 | Qurient Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Inv NCT05992220 | Asan Medical Center | Phase 2 |
| Terminated | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types K NCT05497453 | Omega Therapeutics | Phase 1 / Phase 2 |
| Unknown | Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Can NCT05453383 | Shen Feng | Phase 2 |
| Unknown | Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5 NCT05361538 | Tianjin Third Central Hospital | N/A |
| Completed | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors NCT05293496 | MacroGenics | Phase 1 |
| Terminated | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tu NCT05070247 | Takeda | Phase 1 / Phase 2 |
| Completed | Vascular Invasion Signatures in cfDNA Support Re-staging of Liver Cancer NCT05540925 | Eastern Hepatobiliary Surgery Hospital | — |
| Recruiting | GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies NCT05003895 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma NCT05100082 | Takeda | — |
| Terminated | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors NCT05061537 | Pfizer | Phase 1 |
| Active Not Recruiting | ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk NCT05064553 | Exact Sciences Corporation | — |
| Recruiting | Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC NCT04912765 | National Cancer Centre, Singapore | Phase 2 |
| Completed | Volatile Organic Compounds for the Assessment of Liver Disease NCT04620538 | Imperial College London | — |
| Active Not Recruiting | Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subj NCT03937830 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers NCT04682847 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | — |
| Completed | PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) NCT04484636 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | N/A |
| Terminated | The PLATON Network NCT05489250 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | — |
| Completed | Investigation of Immune Modulation by Modern Acupuncture in Gastroenterologic Cancers NCT04692454 | Taipei Medical University WanFang Hospital | N/A |
| Unknown | High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors NCT04033107 | Zhongnan Hospital | Phase 2 |
| Unknown | Diagnostic Efficacies of Sonazoid-CEUS and EOB-MRI in Patients With High Risk of HCC NCT04212273 | Tianjin Third Central Hospital | N/A |
| Completed | Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC NCT04212286 | Tianjin Third Central Hospital | N/A |
| Unknown | A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With NCT03971201 | White Plains Hospital | Phase 2 |
| Terminated | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma NCT03785210 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sharing Decision-making Program for HCC Patients Treatment Decisions NCT03926039 | National Taipei University of Nursing and Health Sciences | N/A |
| Withdrawn | Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma NCT03748927 | National Cancer Institute (NCI) | — |
| Recruiting | Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patien NCT03787056 | Hospices Civils de Lyon | N/A |
| Completed | Measuring and Improving the Safety of Test Result Follow-Up NCT04166240 | VA Office of Research and Development | N/A |
| Completed | Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular NCT03572582 | AIO-Studien-gGmbH | Phase 2 |
| Terminated | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer NCT03480152 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | DC Bead LUMI (TM) Loaded With Doxorubicin for Intermediate Hepatocellular Carcinoma (HCC) NCT03474354 | Malagari Katerina | — |
| Terminated | Characterization of Methylation Patterns in Hepatocellular Carcinoma NCT04264754 | Nucleix Ltd. | — |
| Completed | Interest of elastoFRM With Force Measure by MRI on Patients With Hepatocellular Cancer NCT02929082 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma NCT03586050 | Ethicon, Inc. | N/A |
| Completed | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers NCT03195699 | Tvardi Therapeutics, Incorporated | Phase 1 |
| Recruiting | Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in P NCT03253536 | Ludwig-Maximilians - University of Munich | — |
| Active Not Recruiting | AFPᶜ³³²T in Advanced HCC NCT03132792 | Adaptimmune | Phase 1 |
| Completed | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. NCT02947165 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR) NCT02958163 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 2 |
| Completed | Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer NCT03037437 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Completed | Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver NCT03151213 | Sherief Abd-Elsalam | Phase 4 |
| Active Not Recruiting | A Longitudinal Observational Study of the Natural History and Management of Patients With HCC NCT02954094 | Target PharmaSolutions, Inc. | — |
| Unknown | Effect of Remote Ischaemic preConditioning on Liver Injury in Patients Undergoing LIVER Resection Surgery NCT03594929 | Singapore General Hospital | N/A |
| Recruiting | Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers NCT02838836 | University of Missouri-Columbia | — |
| Recruiting | Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow NCT03551951 | University of Missouri-Columbia | — |
| Completed | HCC Patient Preferences in Japan NCT02616692 | Bayer | — |
| Terminated | LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors NCT02649868 | National Institutes of Health Clinical Center (CC) | N/A |
| Terminated | Prospective Tumor Response Evaluation NCT02787954 | The University of Texas Health Science Center, Houston | — |
| Completed | Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer NCT02292173 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin NCT02141906 | University of Texas Southwestern Medical Center | Phase 2 |
| Withdrawn | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular NCT02288507 | University of Hawaii | Phase 1 |
| Completed | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer NCT02082210 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Unknown | Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm NCT02528526 | University of Zurich | Phase 1 / Phase 2 |
| Completed | Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer NCT02069145 | OncoMed Pharmaceuticals, Inc. | Phase 1 |
| Completed | Assessment of Frailty in Patients With Advanced Hepatocellular Cancers NCT02482259 | Newcastle-upon-Tyne Hospitals NHS Trust | — |
| Completed | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer NCT01967823 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) NCT01849588 | Massachusetts General Hospital | Phase 4 |
| Terminated | Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer NCT01807156 | Emory University | Phase 2 |
| Unknown | Autologous Natural Killer T Cells Infusion for the Treatment of Cancer NCT01801852 | Chinese PLA General Hospital | N/A |
| Completed | Sorafenib + mFOLFOX for Hepatocellular Carcinoma NCT01775501 | Massachusetts General Hospital | Phase 2 |
| Unknown | Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery NCT01655641 | Tribhuvan University Teaching Hospital, Institute Of Medicine. | Phase 2 / Phase 3 |
| Terminated | Major RF Ablations of Hepatomas Under MR Thermometry Monitoring NCT01486134 | Assistance Publique - Hôpitaux de Paris | N/A |
| Withdrawn | Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma NCT01618253 | Medical College of Wisconsin | Phase 1 |
| Completed | TRC105 for Liver Cancer That Has Not Responded to Sorafenib NCT01375569 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Adult-to-Adult Living Donor Transplant Cohort Study NCT01619475 | Arbor Research Collaborative for Health | — |
| Completed | A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation NCT02073435 | Northwestern University | — |
| Unknown | Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma NCT01078311 | South West Sydney Local Health District | — |
| Terminated | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors NCT01012362 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer NCT01522937 | University of Michigan Rogel Cancer Center | Phase 2 |
| Terminated | Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer NCT01507740 | Medical University Innsbruck | — |
| Completed | Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer NCT00813293 | Beth Israel Deaconess Medical Center | Phase 2 |
| Terminated | Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular C NCT00669136 | Lisa H. Butterfield, Ph.D. | Phase 1 |
| Completed | Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients NCT00997022 | Columbia University | Phase 1 |
| Suspended | Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer NCT00909558 | Envita Medical Center, Inc. | Phase 1 |
| Completed | Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor NCT00706576 | University of Missouri-Columbia | Phase 1 |
| Completed | Study of Postoperative 3D-CRT/IMRT in Hepatocellular Carcinoma NCT01456156 | Chinese Academy of Medical Sciences | N/A |
| Terminated | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer NCT03026803 | City of Hope Medical Center | Phase 2 |
| Completed | Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases NCT00465023 | Massachusetts General Hospital | N/A |
| Terminated | Clinical Application of Image-Guided Liver Surgery NCT00878215 | Washington University School of Medicine | Phase 2 |